Navigation Links
Early In Vivo Visualization of Retinoblastoma Tumors in Histologic Detail

Indianapolis, In. (PRWEB) August 28, 2013

Researchers at the Eugene and Marilyn Glick Eye Institute at the Indiana University School of Medicine have been successful in visualizing retinoblastoma tumors in Tag-RB mice as early as 8 weeks of age using OCT technology. This is one week earlier than reported in the literature.1,2. By 10 weeks of age, retinoblastoma tumors in this transgenic mouse model were clearly delineated within the inner nuclear layer. The Phoenix Research Laboratories Image-Guided OCT facilitates in-vivo imaging of the tumors in histologic detail.

“The strength of in-vivo OCT imaging in mice lies not only in detailing the foci of the lesions within the retinal layers, but in the ability to monitor tumor growth longitudinally with documentation of the invasion or disruption of the inner and outer retina.” notes Tim Corson, PhD, Assistant Professor at the Glick Eye Institute, Indianapolis.

Retinoblastoma is the most common eye malignancy in children, usually affecting those younger than age 5. Early detection is the key to successful treatment of this blinding and potentially lethal cancer. Mouse models of retinoblastoma have provided insights into the development and treatment of tumors in the retina, as well the genetic pattern of inheritance of other cancers.

The Phoenix Image-Guided OCT delivers longitudinal resolution under 2 microns and enables precise OCT scan placement by providing a guide beam in the bright field image. Even small lesions not visible in the bright field image can be detected by OCT, easily scanned and their location referenced.

“We are excited and pleased by the contribution the Phoenix Image-Guided OCT System is making in groundbreaking research such as this retinoblastoma study,” said Bert Massie, PhD, Chairman and CEO of Phoenix Research Labs. “The power of in vivo OCT imaging is fueling earlier detection discoveries while contributing to the understanding of tumorigenesis, morphology and treatment efficacies. We are honored to be playing a role in such impactful scientific advancements.”

About Phoenix Research Labs
Phoenix Research Labs is an animal eye research company focused on developing innovative technologies to advance the study of eye diseases. The Phoenix product line includes the Micron IV Retinal Imaging Microscope, Image-Guided OCT System, Ganzfeld ERG System, Image-Guided Focal ERG System, Image-Guided Laser System and Anterior Segment Image System. With systems located in the US, Europe, Asia and Latin America, Phoenix Research Labs has a global presence in the world ophthalmology research effort. Incorporated in 2008 by Dr. Bert Massie, the company is located in Pleasanton, CA. For more information visit

1.    Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1808-14. In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography. Ruggeri M, Wehbe H, Jiao S, Gregori G, Jockovich ME, Hackam A, Duan Y, Puliafito CA.
2.    Opt Express. 2009 Mar 2;17(5):4074-83. Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography. Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, Murray TG, Puliafito CA.

Media Contacts:

Vicki Hermansen, Director, Marketing & Communications
Eugene and Marilyn Glick Eye Institute
IU School of Medicine Department of Ophthalmology

Melody Bertolucci, Director of Marketing
Phoenix Research Labs

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
2. JCI early table of contents for Aug. 15, 2013
3. JCI early table of contents for Aug. 8, 2013
4. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
5. RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response
6. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
7. Adult cells transformed into early-stage nerve cells, bypassing the pluripotent stem cell stage
8. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
9. Finally, the need of nearly every woman wanting to look more beautiful is fulfilled with Crisalix, the first online direct-to-consumer 3D imaging using standard pictures
10. Bed Bugs Get Family Throwing Nearly All Their Possessions, My Cleaning Offers Help With Complimentary Samples of Non-Pesticide Bed Bug Bully
11. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):